phase readout
saveNCT07370597: LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Jules Bordet Institute. Phase: . Conditions: Prostate Cancer (Adenocarcinoma)
view source ↗
comments(0)
5-min edit window · permanent after that